Physician profile
Todd C Eberle
NPI 1003222043
$1,190.33
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $78.62 · 2021: $250 · 2022: $397 · 2023: $14.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $204.46 | 2019-2022 | |
| Amgen INC. | $95.74 | 2019-2022 | |
| Pfizer INC. | $78.52 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $75.74 | 2019-2022 | |
| Philips North America LLC | $60.82 | 2019-2023 | |
| Biogen, INC. | $60.10 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.12 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.86 | 2022 | |
| Janssen Pharmaceuticals, INC | $45.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.98 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $33.76 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $31.45 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.46 | 2019 | |
| Dexcom, INC. | $27.45 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $26.66 | 2020 | |
| Sanofi Pasteur INC. | $26.03 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $23.30 | 2019-2021 | |
| Therapeuticsmd, INC. | $19.92 | 2019 | |
| Impel Pharmaceuticals INC. | $19.77 | 2022 | |
| Mylan Specialty L.P. | $17.48 | 2019 | |
| Organon LLC | $16.65 | 2022 | |
| Irhythm Technologies, INC. | $15.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.24 | 2019 | |
| Lilly USA, LLC | $13.86 | 2021 | |
| Esperion Therapeutics, INC. | $13.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.05 | 2022 | |
| Endo Pharmaceuticals INC. | $11.43 | 2019 | |
| Daiichi Sankyo INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Eberle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.